Boston, MA According to Avison Young, Juniper Pharmaceuticals has signed a 7,050 s/f lease at 33 Arch St. Avison Young’s Karyn McFarland and Matt Twombly, a principal and vice president, respectively, in the firm’s Boston office, represented Juniper Pharmaceuticals in the transaction. CBRE represented the landlord, TIAA-CREF. Juniper Pharmaceuticals will move from its current location at 4 Liberty Sq.
“Juniper Pharmaceuticals has experienced tremendous growth, doubling in size over the past two years,” said McFarland. “The new space at 33 Arch St. will help the firm as it continues to expand.”
The 33 Arch St. site is located in the between Downtown Crossing and the Financial District. The property provides views of the Charles River and Boston Common, as well as convenient access to four branches of the MBTA and South Station.
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women’s health. Juniper has a commercial product, CRINONE 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies. Juniper Pharmaceuticals is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU. CRINONE is a registered trademark of Allergan, Inc. in the U.S. and of Merck KGaA, Darmstadt, Germany, outside the U.S
Avison Young is one of the world’s fastest-growing commercial real estate services firms. Headquartered in Toronto, Canada, Avison Young is a collaborative, global firm owned and operated by its principals. Founded in 1978, the company comprises 2,000 real estate professionals in 73 offices, providing value-added, client-centric investment sales, leasing, advisory, management, financing and mortgage placement services to owners and occupiers of office, retail, industrial and multi-family properties.
.png)